

REMARKS/ARGUMENTS

In the communication from the Patent Office mailed on June 13, 2003, the communication alleges that several sequences found on page 18 of the present specification do not comply with the requirements for patent applications containing nucleotide and/or amino acid sequences. The communication contends that the sequences identified as a "portion" of a sequence identification number are improper. Accordingly, the specification has been amended to identify the specific residues of the identified portion of the Sequence Identification Numbers.

The communication also required that the specification be amended to include sequence identification numbers next to their respective sequences. While applicants believe that this is not a requirement imposed by 37 CFR 1.821-1.825, in the interest of advancing prosecution, applicants have amended the specification to place sequence identification numbers next to their respective sequences.

Thus, as the specification has been amended so that it is commensurate in scope with the submission of the present Sequence Listing, it is believed that the above-identified application complies with the requirements for patent applications containing nucleotide sequences and/or amino acid sequence disclosures.


Favorable consideration of this application is respectfully requested.

Should there be any matters that need to be resolved in the present application, the Examiner is respectfully requested to contact the undersigned at the telephone number listed below.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17.

Respectfully submitted,

YOUNG & THOMPSON



Philip A. DuBois, Reg. No. 50,696

745 South 23rd Street
Arlington, VA 22202
Telephone (703) 521-2297

PD/fb